Tirzepatide is a novel dual agonist of the GLP-1 and GIP receptors (designated GLP-2T), designed as a single molecule that activates both incretin pathways simultaneously. GLP-1 receptor activation drives insulin secretion, appetite suppression, and slowed gastric emptying, while GIP receptor activation — acting in a glucose-dependent manner — enhances insulin sensitivity and contributes to fat tissue metabolism. The dual-receptor mechanism appears to produce additive or synergistic metabolic effects compared to GLP-1 monotherapy, with tirzepatide demonstrating substantial reductions in body weight and glycemic parameters in research settings.